Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | S100B | P04271 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6141790 | 1.00 | TDP1 (0.62) | TDP1CYP3A4ALOX15TP53THRB | |
| Hydrochloric Acid SCHEMBL27406515 | 1.00 | TDP1 (0.62) | TDP1CYP3A4ALOX15TP53THRB | |
| SCHEMBL33980 | 0.97 | — | — | |
| SCHEMBL29366708 | 0.97 | — | — | |
| Ammonia Solution, Strong SCHEMBL1548755 | 0.94 | TDP1 (0.62) | TDP1CYP3A4ALOX15TP53THRB | |
| SCHEMBL11239230 | 0.94 | TDP1 (0.62) | TDP1CYP3A4ALOX15TP53THRB | |
| Fluoride SCHEMBL18789317 | 0.94 | TDP1 (0.62) | TDP1CYP3A4ALOX15TP53THRB | |
| Methyl Alcohol SCHEMBL11681113 | 0.92 | TDP1 (0.59) | TDP1CYP3A4ALOX15TP53THRB | |
| 2,5-Xylidine SCHEMBL9494012 | 0.87 | TDP1 (0.81) | TDP1CYP3A4ALOX15TP53THRB | |
| SCHEMBL6834418 | 0.87 | TDP1 (0.54) | TDP1CYP3A4ALOX15TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626874-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SPIROCYCLIC KRAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-10-08 | — | — | EP | claimed |
| WO-2025074394-A1 | A PROCESS FOR THE PREPARATION OF BELZUTIFAN AND ITS NOVEL INTERMEDIATES THEREOF | NATCO PHARMA LIMITED (IN) | 2025-04-10 | — | — | WO | claimed |
| CN-117361825-B | Heavy metal treatment method for livestock and poultry manure | 江西正合生态农业有限公司 | 2024-10-01 | — | — | CN | claimed |
| US-20240199569-A1 | PROCESS FOR THE MANUFACTURE OF INHIBITORS OF KRAS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-20 | — | — | US | claimed |
| WO-2024115529-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SPIROCYCLIC KRAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-06 | — | — | WO | claimed |
| CN-117361825-A | Heavy metal treatment method for livestock and poultry manure | 江西正合生态农业有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-107778200-B | Process for the preparation of amitraz | 东莞市东阳光动物保健药品有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-1800185-A | Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes. | BIOVITRUM AB (SE) | 2006-07-12 | — | — | CN | claimed |
| CN-1522245-A | Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-08-18 | — | — | CN | claimed |
| EP-4720678-A1 | SURVIVIN AS A BIOMARKER FOR PREDICTING THE RESPONSIVENESS OF CANCER TREATMENT | Boehringer Ingelheim International GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719603-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2026-04-08 | — | — | EP | disclosed |
| EP-4626874-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SPIROCYCLIC KRAS INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025201480-A1 | SPIRO COMPOUND AS KRAS MUTANT INHIBITOR | 苏州浦合医药科技有限公司 | 2025-10-02 | — | — | WO | disclosed |
| US-20250153157-A1 | PALLADIUM PRECATALYST EMBODIMENTS FOR ENANTIOSELECTIVE CHEMICAL REACTIONS AND METHODS OF MAKING AND USING THE SAME | UVIC IND PARTNERSHIPS INC (CA) | 2025-05-15 | — | — | US | disclosed |
| CN-1522245-A | Substituted sulfonamide compounds, process for their preparation and their use as medicaments for the treatment of CNS disorders, obesity and type II diabetes | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-08-18 | — | — | CN | disclosed |
| EP-1384998-A1 | EYESTRAIN MODEL, METHOD OF CONSTRUCTING THE SAME, EVALUATION METHOD WITH THE USE OF THE MODEL AND DRUGS SCREENED BY USING THE EVALUATION METHOD | Biochemical and Pharmacological Laboratories Inc. (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-0849292-B1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORP (JP) | 2002-08-21 | — | — | EP | disclosed |
| US-6110858-A | AN OLEFIN POLYMERIZATION CATALYST CONSISTS OF A TRANSITION METAL COMPOUND, A MODIFIED CLAY COMPOUND CONTAINING CLAY MINERAL AND AN AMINE COMPOUND AND AN ORGANOALUMINUM COMPOUND | TOSOH CORPORATION (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0849292-A1 | Olefin polymerisation catalysts and processes for producing olefin polymers | TOSOH CORPORATION (JP) | 1998-06-24 | — | — | EP | disclosed |
| US-4963691-A | Spirodilactam derivatives | SHELL OIL COMPANY (US) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199569-A1 | PROCESS FOR THE MANUFACTURE OF INHIBITORS OF KRAS | KRAS, NRAS, HRAS | GAA 820/4885TDP1 2755/4885CYP3A4 2474/4885 |
| US-20250153157-A1 | PALLADIUM PRECATALYST EMBODIMENTS FOR ENANTIOSELECTIVE CHEMICAL REACTIONS AND METHODS OF MAKING AND USING THE SAME | PPOX, PDCD1, DDT | GAA 2177/4885TDP1 1189/4885CYP3A4 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.